Editing
Stones: Evaluation and Medical Management
(section)
Jump to navigation
Jump to search
Warning:
You are not logged in. Your IP address will be publicly visible if you make any edits. If you
log in
or
create an account
, your edits will be attributed to your username, along with other benefits.
Anti-spam check. Do
not
fill this in!
== Follow-up== *'''<span style="color:#ff0000">Labs</span>''' **'''<span style="color:#ff0000">Repeat 24-hour urine collection</span>''' ***'''<span style="color:#ff0000">A single 24-hour urine specimen for stone risk factors should be obtained within 6 months of the initiation of treatment to assess response to dietary and/or medical therapy</span>''' ***'''<span style="color:#ff0000">After the initial follow-up, a single 24-hour urine specimen should be obtained annually or with greater frequency, depending on stone activity, to assess patient adherence and metabolic response</span>''' **'''<span style="color:#ff0000">Periodic blood testing should be obtained to assess for adverse effects in patients on pharmacological therapy.</span>''' ***'''<span style="color:#ff0000">Thiazide therapy may promote hypokalemia and glucose intolerance</span>''' *** '''<span style="color:#ff0000">Allopurinol and tiopronin may cause an elevation in liver enzymes</span>''' ***'''<span style="color:#ff0000">AHA and tiopronin may induce anemia and other hematologic abnormalities</span>''' ***'''<span style="color:#ff0000">Potassium citrate may result in hyperkalemia</span>''' ***'''Patients with undiagnosed primary hyperparathyroidism may develop hypercalcemia after initiation of thiazide therapy''' **Repeat stone analysis, when available, should be obtained especially in patients not responding to treatment *'''<span style="color:#ff0000">Imaging''' ** '''<span style="color:#ff0000">Periodic imaging to assess for stone growth or new stone formation based on stone activity (plain abdominal imaging, renal ultrasonography or low dose CT).''' *'''<span style="color:#ff0000">Patients with struvite stones should be monitored for reinfection with urease-producing organisms and utilize strategies to prevent such occurrences.''' **Monitoring should include surveillance urine culture testing on a periodic basis. In some cases, recurrences may be reduced with long-term, prophylactic antibiotic therapy *If patients remain stone free on their treatment regimen for an extended period of time, discontinuation of follow-up testing may be considered.
Summary:
Please note that all contributions to UrologySchool.com may be edited, altered, or removed by other contributors. If you do not want your writing to be edited mercilessly, then do not submit it here.
You are also promising us that you wrote this yourself, or copied it from a public domain or similar free resource (see
UrologySchool.com:Copyrights
for details).
Do not submit copyrighted work without permission!
Cancel
Editing help
(opens in new window)
Navigation menu
Personal tools
Not logged in
Talk
Contributions
Create account
Log in
Namespaces
Page
Discussion
English
Views
Read
Edit
Edit source
View history
More
Search
Navigation
Main page
Clinical Tools
Guidelines
Chapters
Landmark Studies
Videos
Contribute
For Patients & Families
MediaWiki
Recent changes
Random page
Help about MediaWiki
Tools
What links here
Related changes
Special pages
Page information